Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized placebo-controlled study of roxadustat for anemia in lower-risk myelodysplastic syndrome with low red blood cell transfusion burden
MOH_2017-12-05_000720Phase 3Not yet recruiting
- Sponsor
- FibroGen
- Start
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in myelodysplastic syndrome (MDS) and anaemia comparing roxadustat with placebo (2 arms). Primary endpoint: Red blood cell transfusion independence for at least 56 consecutive days. Planned start Aug 2017; status: not yet recruiting.
02
Drugs
roxadustat
03
Conditions
myelodysplastic syndrome (MDS)anaemia
Beyond the preview
Go deeper on MOH_2017-12-05_000720.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-12-05_000720.